|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Allogene Therapeutics, Inc. (ALLO) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
209,110,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Allogene Therapeutics is a clinical stage immuno-oncology company focused on the development of genetically engineered allogeneic T cell therapies for the treatment of cancer. Co.'s key product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic Chimeric antigen receptor (CAR) T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. Co. is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma, and other blood cancers and solid tumors.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
1,724,327 |
Total Buy Value |
$0 |
$0 |
$0 |
$5,000,680 |
Total People Bought |
0 |
0 |
0 |
2 |
Total Buy Transactions |
0 |
0 |
0 |
2 |
Total Shares Sold |
46,486 |
229,500 |
247,857 |
306,338 |
Total Sell Value |
$65,914 |
$401,998 |
$441,831 |
$603,672 |
Total People Sold |
2 |
8 |
9 |
10 |
Total Sell Transactions |
2 |
11 |
13 |
17 |
End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Messemer Deborah M. |
Director |
|
2025-06-10 |
4 |
AS |
$1.42 |
$52,377 |
D/D |
(36,885) |
107,431 |
|
- |
|
Yoshiyama Annie |
SVP, Finance |
|
2025-04-21 |
4 |
S |
$1.41 |
$13,537 |
D/D |
(9,601) |
130,663 |
|
- |
|
Chang David D |
President and CEO |
|
2025-03-14 |
4 |
S |
$1.96 |
$91,469 |
D/D |
(46,668) |
5,276,569 |
|
- |
|
Beneski Benjamin Machinas |
SVP, Chief Technical Officer |
|
2025-03-14 |
4 |
S |
$1.98 |
$10,839 |
D/D |
(5,488) |
218,507 |
|
- |
|
Beneski Benjamin Machinas |
SVP, Chief Technical Officer |
|
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
31,755 |
223,995 |
|
- |
|
Beneski Benjamin Machinas |
SVP, Chief Technical OfficerOf |
|
2025-03-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
192,240 |
|
- |
|
Messemer Deborah M. |
Director |
|
2025-02-18 |
4 |
AS |
$2.43 |
$32,351 |
D/D |
(13,313) |
144,316 |
|
- |
|
Parker Geoffrey M. |
CHIEF FINANCIAL OFFICER |
|
2025-02-03 |
4 |
S |
$1.73 |
$7,545 |
D/D |
(4,361) |
1,301,540 |
|
- |
|
Moore Timothy L. |
Chief Technical Officer |
|
2025-02-03 |
4 |
S |
$1.71 |
$25,216 |
D/D |
(14,746) |
250,713 |
|
- |
|
Roberts Zachary |
EVP of R&D |
|
2025-02-03 |
4 |
S |
$1.70 |
$32,014 |
D/D |
(18,832) |
643,135 |
|
- |
|
Chang David D |
President and CEO |
|
2025-02-03 |
4 |
S |
$1.68 |
$77,285 |
D/D |
(46,003) |
5,317,237 |
|
- |
|
Douglas Earl Martin |
SVP, General Counsel |
|
2025-02-03 |
4 |
S |
$1.71 |
$10,951 |
D/D |
(6,404) |
587,848 |
|
- |
|
Yoshiyama Annie |
SVP, Finance |
|
2025-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
36,232 |
137,990 |
|
- |
|
Parker Geoffrey M. |
CHIEF FINANCIAL OFFICER |
|
2025-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
173,913 |
1,305,901 |
|
- |
|
Roberts Zachary |
EVP of R&D |
|
2025-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
173,913 |
661,967 |
|
- |
|
Belldegrun Arie |
Director |
|
2025-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
369,957 |
2,236,816 |
|
- |
|
Douglas Earl Martin |
SVP, General Counsel |
|
2025-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
144,928 |
594,252 |
|
- |
|
Chang David D |
President and CEO |
|
2025-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
552,174 |
5,363,240 |
|
- |
|
Roberts Zachary |
EVP of R&D |
|
2025-01-21 |
4 |
S |
$1.78 |
$48,414 |
D/D |
(27,199) |
488,054 |
|
- |
|
Messemer Deborah M. |
Director |
|
2024-12-09 |
4 |
S |
$2.18 |
$19,916 |
D/D |
(9,136) |
157,629 |
|
- |
|
Humer Franz B |
Director |
|
2024-12-05 |
4 |
S |
$2.16 |
$19,917 |
D/D |
(9,221) |
307,507 |
|
- |
|
Parker Geoffrey M. |
CHIEF FINANCIAL OFFICER |
|
2024-10-21 |
4 |
D |
$2.84 |
$103,387 |
D/D |
(36,404) |
1,131,988 |
|
- |
|
Douglas Earl Martin |
SVP, General Counsel |
|
2024-08-21 |
4 |
D |
$2.79 |
$78,843 |
D/D |
(28,310) |
449,324 |
|
- |
|
Messemer Deborah M. |
|
|
2024-06-18 |
4 |
AS |
$2.28 |
$42,488 |
D/D |
(18,641) |
166,765 |
|
- |
|
Yoshiyama Annie |
SVP, Finance |
|
2024-06-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
101,758 |
|
- |
|
254 Records found
|
|
Page 1 of 11 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|